Modality
Fusion Protein
MOA
BCL-2i
Target
C5
Pathway
STING
CFCLLRSV
Development Pipeline
Preclinical
~Sep 2012
→ ~Dec 2013
Phase 1
~Mar 2014
→ ~Jun 2015
Phase 2
~Sep 2015
→ ~Dec 2016
Phase 3
Mar 2017
→ Nov 2028
Phase 3Current
NCT07968685
1,732 pts·CF
2019-01→2028-11·Recruiting
NCT03769799
1,579 pts·CLL
2017-03→2025-09·Terminated
3,311 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-09-077mo agoPh3 Readout· CLL
2028-11-022.6y awayPh3 Readout· CF
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P3
Termina…
P3
Recruit…
Catalysts
Ph3 Readout
2025-09-07 · 7mo ago
CLL
Ph3 Readout
2028-11-02 · 2.6y away
CF
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07968685 | Phase 3 | CF | Recruiting | 1732 | ORR |
| NCT03769799 | Phase 3 | CLL | Terminated | 1579 | DAS28 |
Competitors (10)